SCIRIA Openmind seminar series, architecture/pure data/graphical programming

SCIRIA ‘OpenMind’ was a regular seminar series for University of the Arts London staff, MA and PhD students and the public. The seminars were hosted at Camberwell College of Arts and Chelsea College of Art and Design. The footage, audio and flyers offer an insight into the research processes and activities of SCIRIA members, associates and external speakers

The Aethera Trial: An Ongoing Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

n/

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Abstract Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin lymphoma (HL) patients at high risk for relapse. The study met its primary endpoint: significant improvement in progression-free survival (PFS) per independent review with BV versus placebo (hazard ratio [HR]=0.57, P=0.001) (Moskowitz, 2015). The 2 most common adverse events (AEs) in the BV- treatment group were peripheral sensory neuropathy (56%) and neutropenia (35%). We are presenting updated efficacy and safety data after approximately 1 additional year of follow-up after the primary analysis. Methods Patients were randomized to receive BV 1.8 mg/kg q3wk or placebo for 16 cycles (approximately 12 months), 30-45 days after transplantation. Randomization was stratified by response to frontline therapy and by best clinical response to pre-ASCT salvage therapy. Patients whose disease had progressed after salvage treatment were not eligible. Patients received CT scans quarterly for the first year and then at 18 and 24 months during long-term follow-up (LTFU). Clinical lymphoma assessments were performed at each cycle of treatment, quarterly during the first year of LTFU, and every 6 months thereafter. AEs were collected for 30 days after the end of treatment, except for peripheral neuropathies and secondary malignancies, which were followed throughout LTFU. Clinical responses to subsequent BV treatment received after progression were also recorded. Results A total of 329 patients were randomized to the BV- (n=165) or placebo- (n=164) treatment arms. Median PFS per investigator assessment was not reached (95% CI not estimable [NE]-NE) in the BV arm and was 15.8 months (95% CI 8.5-44.0) in the placebo arm (HR=0.52, 95% CI 0.37-0.71). A sustained plateau with substantial separation is evident between both treatment groups, with improved PFS at 3-years post-randomization with BV consolidation versus placebo (Figure). The 3-year PFS rate was 61% (95% CI 52-68) for the BV arm and 43% (95% CI 36-51) for the placebo arm. Six PFS events (2 progressions and 4 deaths) were recorded after the 24-month evaluation period in the BV arm and 3 in the placebo arm (2 progressions and 1 death). The HR for PFS per independent review was 0.58 (95% CI 0.41-0.82). No new secondary malignancies have been observed since the primary analysis. The number of cases were comparable between the 2 treatment arms (n=4 BV, n=2 placebo). Malignancies on the BV arm included bladder cancer, lung cancer, pancreatic cancer, and myelodysplastic syndrome (n=1 each). In the placebo arm, secondary malignancies included mantle cell lymphoma and myelodysplastic syndrome (n=1 each). Among the 112 patients on the BV arm who experienced treatment-emergent peripheral neuropathy based on a Standardised Medical Dictionary for Regulatory Activities (MedDRA) Query (SMQ) analysis, 99 patients (88%) experienced some improvement (23%) or complete resolution (65%) of neuropathy symptoms at the time of analysis. Discontinuation of treatment due to an AE occurred in 54 patients (33%) on the BV arm, most commonly due to peripheral sensory and motor neuropathies (14% and 7%, respectively). Patients who discontinued treatment as a result of an AE received a median of 9.5 cycles (range, 1 to 15) on the BV arm. The 2-year PFS rate in these patients was 69% (95% CI 54-79) versus 82% (95% CI 71-89) for patients who completed all 16 treatment cycles. Conclusions Consolidation treatment with BV in HL patients at high risk of relapse after ASCT showed an improvement in PFS versus placebo, approximately 3 years since the last patient was randomized. Kaplan-Meier analysis of PFS per investigator assessment showed a continued benefit of BV consolidation. No additional secondary malignancies have been observed in either treatment arm and most patients experienced resolution of peripheral neuropathy symptoms. We are currently analyzing clinical responses to BV treatment after disease progression. Figure 1. Progression-Free Survival per Investigator Assessment Figure 1. Progression-Free Survival per Investigator Assessment Disclosures Sweetenham: Seattle Genetics Inc.: Honoraria, Research Funding, Speakers Bureau. Off Label Use: Brentuximab vedotin is indicated in the US for treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates and for the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen. This study investigates the use of brentuximab vedotin for consolidation therapy soon after ASCT. . Walewski:Mundipharma; Roche; Takeda: Honoraria, Other: Travel expenses; Amgen; Boehringer Ingelheim; Celgene; Janssen-Cilag; Mundipharma; Roche; Takeda; Teva: Consultancy; Bayer (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celltrion (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Mundipharma (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Geneti: Research Funding. Nademanee:Celgene: Consultancy; Seattle Genetics Inc.: Research Funding; Spectrum: Research Funding; Gilead: Consultancy. Masszi:Novartis Pharmaceuticals Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Agura:Seattle Genetics Inc.: Research Funding. Holowiecki:Seattle Genetics Inc.: Research Funding; Takeda: Other: Travel expenses. Abidi:Seattle Genetics Inc.: Research Funding. Chen:Gilead: Consultancy, Other: Advisory Board; Janssen: Consultancy, Other: Advisory Board; Seattle Genetics: Consultancy, Other: Advisory Board; Genentech, Inc.: Consultancy, Other: Advisory Board. Stiff:Seattle Genetics Inc.: Consultancy, Honoraria, Research Funding. Viviani:Italfarmaco SpA: Consultancy; Teva Italia SpA: Consultancy; Takeda Italia SpA: Consultancy; Takeda International: Consultancy. Carella:Seattle Genetics Inc.: Research Funding. Osmanov:Seattle Genetics Inc.: Research Funding. Bachanova:Seattle Genetics Inc.: Consultancy, Research Funding. Sureda:Seattle Genetics Inc.: Research Funding; Takeda: Consultancy, Honoraria, Speakers Bureau. Huebner:Takeda Pharmaceuticals International Co.: Employment, Equity Ownership. Larsen:Seattle Genetics Inc.: Employment, Equity Ownership. Hunder:Seattle Genetics Inc.: Employment, Equity Ownership

The City Quartered

My film for the 'Beyond The Digital Surface'exhibition, is an attempt to explore the nature of cities, in particular London, by using the idea of captured digital surfaces. In this project I have decided to take two elements and try to stitch them together to hint at the nature of my urban surroundings, London. The two elements I have chosen are, architectural structure, and architectural surface. The structure I have used is from an old map of Seoul. This map indicates the very formal nature of a walled city, and exemplifies the relationship between structures of habitation, and mankind's desire to formalise his surroundings. Walled Seoul, has a set of strong features .The city had four main gates, North, South, East and West. Each gate has its own properties such as colour and a mythical animal. Traversing the city is the river Han. It was the North, South, East and West aspects of the city that I decided to use as a structure for my film. I have imposed on that structure the surfaces to be found in London. It is these surfaces that need re-inventing, to be presented in a manner that reflect the nature and re-purposing of physical structures in the 21st Century. The treatment for each area attempts to play with the contemporary transient nature of the meaning of buildings in London. As digital technology makes redundant the need for the traditional building types, vast areas can be re-purposed utilised and the original nature of areas gets mixed up with the contemporary purpose. No longer do the facades display the purpose of the building and so the surfaces have just become patterns that perhaps can be deconstructed and rebuilt to relate to a new medium in a new er

Temporal Facades

Temporal Facades was selected by the London Architecture Biennale, the committee was made up from 19 panel members, including Peter Ackroyd, Paul Finch, Zaha Hadid and Rowan Moore. The work was shown for 10 days in Brewers Yard in Clerkenwell, in the offices of BDP Architects. The installation consisted of 12, 42 inch Plasma screens, arranged in the glass façade of an annex building in the middle of the square. The project focussed on the relationship between modern London’s dematerialised working practices, the banking industry typifying this, and the more physical spaces of the city. The locations of interest in the films were selected along the route of the biennale. This started in Southwark Cathedral, and ended in Kings Cross. The selected ‘Nodes’ were Borough Market, Tate Modern, St.Pauls Cathedral, Smithfield Market, Clerkenwell Green, and Kings Cross. All of these spaces celebrate their ‘physicality’

Sonicity_Archeology of the Future

This project was carried out with my collaborators within the group D-Fuse. We were invited to submit a proposal for an ‘art event’ to be held in Ostienze Market, a district in the southern part of Rome. The market had been closed down and the local authority wished to redevelop it. The organisers of the event wished to hand the space over to artists to see how their interpretation of the space could suggest alternative use. Artists such as Achim Wollscheid, Justin Bennet and Janek Schaefer were also invited. Our proposal focused on the history of Rome. This is an aspect of the city that it cannot ignore. The center of Rome is dominated by the remains of the Roman Empire. This history sits alongside contemporary Rome, but does not stifle it. The layers of Rome’s past are carved out, and it was this layering that became the focus of the proposal. The re-invent Ostienze, we needed to reveal the layers of the future. To do this we filmed the disused market in a specific manner. By holding the camera vertically we followed [traced] the walls and structures of the existing buildings. This footage was then edited to into separate films that could be mixed at a live event. The Spanish musician Fibla, took the footage we created to develop a sound score which he would also play live. Our initial idea was to re-instate the flow of goods from delivery, to the warehouse’s, to the market place, all of which traverse the Tiber river, the main road south out of Rome and a railway line, in and out of Rome. The idea was used as a focal point for a lecture given to Architectural Students from the University of Rome

growth data

Growth rate data. ID (individual ID#), family, Phosphorus treatment (high P=HF, low P=LF), predator cue(np=no cue, p=predator cue), sex, age in days, growth (growth rate [head length/age]), head length (mm), ln(growth rate)

Female fecundity data

Female fecundity data. Family, Phosphorus treatment (high=high P, low=low P), predator cue (p=predator cue, np=no cue), cup (id#), head length, whether the female was cannibalized by males, fecundity trait (egg number, egg volume, or number of neonates[offsp_nu]), fecundity trait value, ln(head length), ln(fecund_value)

Family means tradeoff

Family means for tradeoff analysis. Family, P treatment (high P=HF, low P=LF), Predator cue (NP=no cue, P=predator cue), residual antenna size (regressed against head length), resid posterior gnathopod size (against head length), and growth rate (ln-transformed) are provided